Structural and mechanistic commonalities of amyloid-beta and the prion protein

Prion

Volumn 5, Issue 3, 2011, Pages 126-137

  Da Costa Dias, Bianca ^a   Jovanovic, Katarina ^a   Gonsalves, Danielle ^a   Weiss, Stefan F T ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

37 kDa 67 kDa laminin receptor; Alzheimer disease; Amyloid ; Apoptosis; Prion proteins

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BETA SECRETASE; CELL SURFACE PROTEIN; CELL SURFACE RECEPTOR; CLUSTERIN; GAMMA SECRETASE; GLYCOSAMINOGLYCAN; LAMININ; LAMININ RECEPTOR; OLIGOMER; PRION PROTEIN; TAU PROTEIN;

AGGRESSION; ALZHEIMER DISEASE; APOPTOSIS; CELL DEATH; COGNITIVE DEFECT; CONFUSION; DEGENERATIVE DISEASE; FAMILIAL DISEASE; GENE; GENE MUTATION; GENETIC RISK; HALLUCINATION; HUMAN; LANGUAGE DISABILITY; MEMORY DISORDER; NEUROPATHOLOGY; NONHUMAN; PARANOIA; PRION DISEASE; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PSEN 1 GENE; PSEN 2 GENE; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; HUMANS; MODELS, BIOLOGICAL; RECEPTORS, IMMUNOLOGIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80052804919     PISSN: 19336896     EISSN: 1933690X     Source Type: Journal    
DOI: 10.4161/pri.5.3.17025     Document Type: Review

References (113)

1. Forloni G, Balducci C. beta-amyloid oligomers and prion protein: Fatal attraction? Prion 2011; 5:10-5.
2. Mount C, Downton C. Alzheimer disease: progress or profit? Nat Med 2006; 12:780-4. (Pubitemid 44050066)
3. Palmer AM. Neuroprotective therapeutics for Alzheimer's disease: progress and prospects. Trends Pharmacol Sci 2011; 32:141-7.
4. Selkoe DJ. Alzheimer's disease: genes, proteins and therapy. Physiol Rev 2001; 81:741-66. (Pubitemid 32267077)
5. Burns A, Iliffe S. Alzheimer's disease. BMJ 2009; 338:158.
6. Jarrett JT, Berger EP, Lansbury PT Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993; 32:4693-7. (Pubitemid 23162022)
7. Dickson DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997; 56:321-39. (Pubitemid 27465015)
8. Pimplikar SW. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int J Biochem Cell Biol 2009; 41:1261-8.
9. Iqbal K, Liu F, Gong CX, Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 2010; 7:656-64.
10. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000; 405:360-4. (Pubitemid 30337070)
11. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999; 402:615-22. (Pubitemid 129516324)
12. Braak H, Braak E, Bohl J, Bratzke H. Evolution of Alzheimer's disease related cortical lesions. J Neural Transm Suppl 1998; 54:97-106. (Pubitemid 28539346)
13. Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003; 60:1495-500. (Pubitemid 36559525)
14. Josephs KA, Whitwell JL, Ahmed Z, Shiung MM, Weigand SD, Knopman DS, et al. Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol 2008; 63:204-12. (Pubitemid 351355299)
15. Stanford PM, Halliday GM, Brooks WS, Kwok JB, Storey CE, Creasey H, et al. Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations. Brain 2000; 123:880-93. (Pubitemid 30224185)
16. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349:704-6. (Pubitemid 21912142)
17. Selkoe DJ. Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol 1994; 10:373-403. (Pubitemid 24372824)
18. Haass C, Hung AY, Selkoe DJ. Processing of beta-amyloid precursor protein in microglia and astrocytes favors an internal localization over constitutive secretion. J Neurosci 1991; 11:3783-93.
19. Ring S, Weyer SW, Kilian SB, Waldron E, Pietrzik CU, Filippov MA, et al. The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral and electrophysiological abnormalities of APP-deficient mice. J Neurosci 2007; 27:7817-26. (Pubitemid 47093823)
20. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010; 330:1774.
21. Anderson JP, Esch FS, Keim PS, Sambamurti K, Lieberburg I, Robakis NK. Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells. Neurosci Lett 1991; 128:126-8.
22. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992; 359:325-7.
23. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995; 38:643-8.
24. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996; 2:864-70. (Pubitemid 26296755)
25. Fahrenholz F, Gilbert S, Kojro E, Lammich S, Postina R. Alpha-secretase activity of the disintegrin metalloprotease ADAM 10. Influences of domain structure. Ann NY Acad Sci 2000; 920:215-22. (Pubitemid 32056572)
26. Asai M, Hattori C, Szabo B, Sasagawa N, Maruyama K, Tanuma S, et al. Putative function of ADAM9, ADAM10 and ADAM17 as APP alpha-secretase. Biochem Biophys Res Commun 2003; 301:231-5. (Pubitemid 36268873)
27. Tanabe C, Hotoda N, Sasagawa N, Sehara-Fujisawa A, Maruyama K, Ishiura S. ADAM19 is tightly associated with constitutive Alzheimer's disease APP alpha-secretase in A172 cells. Biochem Biophys Res Commun 2007; 352:111-7. (Pubitemid 44821101)
28. Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional and synaptic functions. J Neurosci 2005; 25:11693-709. (Pubitemid 43098462)
29. O'Connor T, Sadleir KR, Maus E, Velliquette RA, Zhao J, Cole SL, et al. Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. Neuron 2008; 60:988-1009.
30. Guglielmotto M, Aragno M, Autelli R, Giliberto L, Novo E, Colombatto S, et al. The upregulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. J Neurochem 2009; 108:1045-56.
31. Omar A, Jovanovic K, Da Costa Dias B, Gonsalves D, Moodley K, Caveney R, et al. Patented biological approaches for the therapeutic modulation of the 37 kDa/67 kDa laminin receptor. Expert Opin Ther Pat 2011; 21:35-53.
32. Mbazima V, Da Costa Dias B, Omar A, Jovanovic K, Weiss SF. Interactions between PrP(c) and other ligands with the 37-kDa/67-kDa laminin receptor. Front Biosci 2010; 15:1150-63.
33. Wolfe MS. Inhibition and modulation of gamma-secretase for Alzheimer's disease. Neurotherapeutics 2008; 5:391-8. (Pubitemid 351952492)
34. Chow VW, Mattson MP, Wong PC, Gleichmann M. An overview of APP processing enzymes and products. Neuromolecular Med 2010; 12:1-12.
35. Wakabayashi T, De Strooper B. Presenilins: members of the gamma-secretase quartets, but part-time soloists too. Physiology (Bethesda) 2008; 23:194-204.
36. Bettens K, Sleegers K, Van Broeckhoven C. Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet 2010; 19:4-11.
37. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995; 269:973-7.
38. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006; 38:24-6. (Pubitemid 43011878)
39. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997; 20:154-9. (Pubitemid 27116286)
40. Cruts M, Van Broeckhoven C. Presenilin mutations in Alzheimer's disease. Hum Mutat 1998; 11:183-90. (Pubitemid 28132873)
41. Kumar-Singh S, Theuns J, Van Broeck B, Pirici D, Vennekens K, Corsmit E, et al. Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat 2006; 27:686-95.
42. Strittmatter WJ, Saunders AM, Schmechel D, Pericak- Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993; 90:1977-81. (Pubitemid 23069980)
43. Bertram L, Tanzi RE. Alzheimer's disease: one disorder, too many genes? Hum Mol Genet 2004; 13:135-41.
44. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006; 63:168-74. (Pubitemid 43213878)
45. Dermaut B, Croes EA, Rademakers R, Van den Broeck M, Cruts M, Hofman A, et al. PRNP Val129 homozygosity increases risk for early-onset Alzheimer's disease. Ann Neurol 2003; 53:409-12. (Pubitemid 36258648)
46. Riemenschneider M, Klopp N, Xiang W, Wagenpfeil S, Vollmert C, Muller U, et al. Prion protein codon 129 polymorphism and risk of Alzheimer disease. Neurology 2004; 63:364-6. (Pubitemid 38971146)
47. Bitan G, Vollers SS, Teplow DB. Elucidation of primary structure elements controlling early amyloid beta-protein oligomerization. J Biol Chem 2003; 278:34882-9. (Pubitemid 37102247)
48. Teplow DB, Lazo ND, Bitan G, Bernstein S, Wyttenbach T, Bowers MT, et al. Elucidating amyloid beta-protein folding and assembly: A multidisciplinary approach. Acc Chem Res 2006; 39:635-45.
49. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 2006; 572:477-92.
50. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30:572-80.
51. Nordberg A. Amyloid plaque imaging in vivo: current achievement and future prospects. Eur J Nucl Med Mol Imaging 2008; 35:46-50.
52. Lesne S, Kotilinek L, Ashe KH. Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function. Neuroscience 2008; 151:745-9.
53. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14:837-42.
54. Marchesi VT. Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. FASEB J 2011; 25:5-13.
55. Bartzokis G. Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol Aging 2009.
56. Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, et al. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 2010; 66:739-54.
57. Bi X, Gall CM, Zhou J, Lynch G. Uptake and pathogenic effects of amyloid beta peptide 1-42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists. Neuroscience 2002; 112:827-40. (Pubitemid 34667047)
58. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992; 12:376-89.
59. Stefani M. Biochemical and biophysical features of both oligomer/fibril and cell membrane in amyloid cytotoxicity. FEBS J 2010; 277:4602-13.
60. Sepulveda FJ, Parodi J, Peoples RW, Opazo C, Aguayo LG. Synaptotoxicity of Alzheimer beta amyloid can be explained by its membrane perforating property. PLoS One 2010; 5:11820.
61. Qiu L, Lewis A, Como J, Vaughn MW, Huang J, Somerharju P, et al. Cholesterol modulates the interaction of beta-amyloid peptide with lipid bilayers. Biophys J 2009; 96:4299-307.
62. Sakurai T, Kaneko K, Okuno M, Wada K, Kashiyama T, Shimizu H, et al. Membrane microdomain switching: a regulatory mechanism of amyloid precursor protein processing. J Cell Biol 2008; 183:339-52.
63. Verdier Y, Penke B. Binding sites of amyloid beta-peptide in cell plasma membrane and implications for Alzheimer's disease. Curr Protein Pept Sci 2004; 5:19-31. (Pubitemid 38279402)
64. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007; 316:750-4. (Pubitemid 46717684)
65. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010; 142:387-97.
66. Beck K, Hunter I, Engel J. Structure and function of laminin: anatomy of a multidomain glycoprotein. FASEB J 1990; 4:148-60.
67. Kibbey MC, Jucker M, Weeks BS, Neve RL, Van Nostrand WE, Kleinman HK. beta-Amyloid precursor protein binds to the neurite-promoting IKVAV site of laminin. Proc Natl Acad Sci USA 1993; 90:10150-3. (Pubitemid 23328269)
68. Koo EH, Park L, Selkoe DJ. Amyloid beta-protein as a substrate interacts with extracellular matrix to promote neurite outgrowth. Proc Natl Acad Sci USA 1993; 90:4748-52. (Pubitemid 23148983)
69. Castillo GM, Lukito W, Peskind E, Raskind M, Kirschner DA, Yee AG, et al. Laminin inhibition of beta-amyloid protein (Abeta) fibrillogenesis and identification of an Abeta binding site localized to the globular domain repeats on the laminin a chain. J Neurosci Res 2000; 62:451-62.
70. Mehrpour M, Codogno P. Prion protein: From physiology to cancer biology. Cancer Lett 2010; 290:1-23.
71. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998; 95:13363-83. (Pubitemid 28525623)
72. Morel E, Andrieu T, Casagrande F, Gauczynski S, Weiss S, Grassi J, et al. Bovine prion is endocytosed by human enterocytes via the 37 kDa/67 kDa laminin receptor. Am J Pathol 2005; 167:1033-42. (Pubitemid 41416255)
73. Gauczynski S, Peyrin JM, Haik S, Leucht C, Hundt C, Rieger R, et al. The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein. EMBO J 2001; 20:5863-75. (Pubitemid 33049262)
74. Gauczynski S, Nikles D, El-Gogo S, Papy-Garcia D, Rey C, Alban S, et al. The 37-kDa/67-kDa laminin receptor acts as a receptor for infectious prions and is inhibited by polysulfated glycanes. J Infect Dis 2006; 194:702-9. (Pubitemid 44297858)
75. Kolodziejczak D, Da Costa Dias B, Zuber C, Jovanovic K, Omar A, Beck J, et al. Prion interaction with the 37-kDa/67-kDa laminin receptor on enterocytes as a cellular model for intestinal uptake of prions. J Mol Biol 2010; 402:293-300.
76. Da Costa Dias B, Jovanovic K, Weiss SF. Alimentary prion infections: Touchdown in the intestine. Prion 2011; 5:6-9.
77. Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci 2001; 24:519-50. (Pubitemid 32695238)
78. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009; 457:1128-32.
79. Chen S, Yadav SP, Surewicz WK. Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues. J Biol Chem 2010; 285:26377-83.
80. Parkin ET, Watt NT, Hussain I, Eckman EA, Eckman CB, Manson JC, et al. Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc Natl Acad Sci USA 2007; 104:11062-7. (Pubitemid 47175226)
81. Kellett KA, Hooper NM. Prion protein and Alzheimer disease. Prion 2009; 3:190-4.
82. Vincent B, Sunyach C, Orzechowski HD, St. George-Hyslop P, Checler F. p53-Dependent transcriptional control of cellular prion by presenilins. J Neurosci 2009; 29:6752-60.
83. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci 2003; 26:207-14. (Pubitemid 36412003)
84. Brown DR. Copper and prion disease. Brain Res Bull 2001; 55:165-73. (Pubitemid 32722156)
85. Barnham KJ, Cappai R, Beyreuther K, Masters CL, Hill AF. Delineating common molecular mechanisms in Alzheimer's and prion diseases. Trends Biochem Sci 2006; 31:465-72. (Pubitemid 44108660)
86. Vincent B, Paitel E, Saftig P, Frobert Y, Hartmann D, De Strooper B, et al. The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein. J Biol Chem 2001; 276:37743-6.
87. Cisse MA, Sunyach C, Lefranc-Jullien S, Postina R, Vincent B, Checler F. The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity. J Biol Chem 2005; 280:40624-31. (Pubitemid 41780553)
88. Jobling MF, Stewart LR, White AR, McLean C, Friedhuber A, Maher F, et al. The hydrophobic core sequence modulates the neurotoxic and secondary structure properties of the prion peptide 106-126. J Neurochem 1999; 73:1557-65. (Pubitemid 29440157)
89. Tagliavini F, Prelli F, Verga L, Giaccone G, Sarma R, Gorevic P, et al. Synthetic peptides homologous to prion protein residues 106-147 form amyloid-like fibrils in vitro. Proc Natl Acad Sci USA 1993; 90: 9678-82. (Pubitemid 23315849)
90. Brown DR, Schmidt B, Kretzschmar HA. Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Nature 1996; 380:345-7. (Pubitemid 26097115)
91. Salmona M, Malesani P, De Gioia L, Gorla S, Bruschi M, Molinari A, et al. Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106-126. Biochem J 1999; 342:207-14. (Pubitemid 29410867)
92. Wang KS, Kuhn RJ, Strauss EG, Ou S, Strauss JH. High-affinity laminin receptor is a receptor for Sindbis virus in mammalian cells. J Virol 1992; 66:4992-5001.
93. Thepparit C, Smith DR. Serotype-specific entry of dengue virus into liver cells: identification of the 37-kilodalton/67-kilodalton high-affinity laminin receptor as a dengue virus serotype 1 receptor. J Virol 2004; 78:12647-56. (Pubitemid 39458782)
94. Kinoshita K, Kaneda Y, Sato M, Saeki Y, Wataya-Kaneda M, Hoffmann A. LBP-p40 binds DNA tightly through associations with histones H2A, H2B and H4. Biochem Biophys Res Commun 1998; 253:277-82. (Pubitemid 29026694)
95. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007; 35:495-516. (Pubitemid 46911891)
96. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407:770-6.
97. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003; 10:26-35. (Pubitemid 36511830)
98. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80:293-9.
99. Henry H, Thomas A, Shen Y, White E. Regulation of the mitochondrial checkpoint in p53-mediated apoptosis confers resistance to cell death. Oncogene 2002; 21:748-60. (Pubitemid 34146287)
100. Hussein MR, Haemel AK, Wood GS. Apoptosis and melanoma: molecular mechanisms. J Pathol 2003; 199:275-88. (Pubitemid 36266850)
101. Hu W, Kavanagh JJ. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 2003; 4:721-9. (Pubitemid 37527207)
102. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999; 397:441-6.
103. Wu M, Xu LG, Li X, Zhai Z, Shu HB. AMID, an apoptosis-inducing factor-homologous mitochondrion-associated protein, induces caspase-independent apoptosis. J Biol Chem 2002; 277:25617-23. (Pubitemid 34951879)
104. van Loo G, Schotte P, van Gurp M, Demol H, Hoorelbeke B, Gevaert K, et al. Endonuclease G: a mitochondrial protein released in apoptosis and involved in caspase-independent DNA degradation. Cell Death Differ 2001; 8:1136-42. (Pubitemid 34048469)
105. Mattson MP, Tomaselli KJ, Rydel RE. Calcium-destabilizing and neurodegenerative effects of aggregated beta-amyloid peptide are attenuated by basic FGF. Brain Res 1993; 621:35-49. (Pubitemid 23242158)
106. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 1994; 77:817-27. (Pubitemid 24187680)
107. Eckert A, Keil U, Marques CA, Bonert A, Frey C, Schussel K, et al. Mitochondrial dysfunction, apoptotic cell death and Alzheimer's disease. Biochem Pharmacol 2003; 66:1627-34. (Pubitemid 38373355)
108. El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 1996; 382:716-9. (Pubitemid 26282177)
109. Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, et al. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 1999; 286:2352-5. (Pubitemid 30016899)
110. Small DH, Mok SS, Bornstein JC. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci 2001; 2:595-8. (Pubitemid 33679833)
111. Susantad T, Smith DR. siRNA-mediated silencing of the 37/67-kDa high affinity laminin receptor in Hep3B cells induces apoptosis. Cell Mol Biol Lett 2008; 13:452-64.
112. Chen Q, Schubert D. Presenilin-interacting proteins. Expert Rev Mol Med 2002; 4:1-18.
113. Da Costa Dias B, Weiss SF. A kiss of a prion: new implications for oral transmissibility. J Infect Dis 2010; 201:1615-1616.